Drugs / Travoprost
Travoprost
also known as
Travatan · OTX-TIC · Travatan Z · ENV515-1 · ENV515-3 · ENV515-3-2 · Gen 2 Travoprost Intracameral Implant · iDose TR · +5 more
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | IDOSE TR | — | 2026-01-27 | fda.gov ↗ |
| Label expansion | US (FDA) | TRAVATAN Z | — | 2010-08-31 | fda.gov ↗ |
| Label expansion | US (FDA) | TRAVATAN | — | 2003-02-13 | fda.gov ↗ |
| Approved | EU (EMA) | Travatan | — | 2001-11-27 | europa.eu ↗ |
| Approved | US (FDA) | TRAVATAN | — | 2001-03-16 | fda.gov ↗ |
Trials 80 · started per year
today
US approved 2001
EU approved 2001
1
2
3
3
2
4
9
7
4
5
7
5
4
1
2
3
4
1
3
1
3
2
2
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04360174 | Apr 2018 → May 2021 | ocular hypertension, open-angle glaucoma | Ocular Therapeutix, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01845038 | Apr 2013 → Mar 2014 | glaucoma | Ocular Therapeutix, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01658839 | Jan → Jul 2013 | glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT07075718 | Jun 2025 → Mar 2028 expected | glaucoma | Glaukos Corporation | Recruiting | No outcome recorded |
| Phase 2 | NCT06152861 | Nov 2023 → Aug 2024 | ocular hypertension, open-angle glaucoma | Glaukos Corporation | Unknown | No outcome recorded |
| Phase 2 | NCT05335122 | Mar 2022 → Jan 2024 | ocular hypertension, open-angle glaucoma | Ocular Therapeutix, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT06582732 | Mar 2021 → Nov 2023 | ocular hypertension, open-angle glaucoma | Glaukos Corporation | Completed | No outcome recorded |
| Phase 2 | NCT04615403 | Nov 2020 → Feb 2022 | open-angle glaucoma | Glaukos Corporation | Completed | No outcome recorded |
| Phase 2 | NCT02754596 | Mar 2016 → Aug 2017 | open-angle glaucoma | Glaukos Corporation | Completed | No outcome recorded |
| Phase 2 | NCT02371746 | Jan 2015 → Feb 2019 | glaucoma | Envisia Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01298687 | Feb → Apr 2011 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 2 | NCT00637130 | Oct 2007 → Jan 2008 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 2 | NCT00527501 | Aug → Dec 2007 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 329 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT07495852 | Feb 2026 → Jun 2028 expected | glaucoma | Glaukos Corporation | Recruiting | No outcome recorded |
| Phase 3 | NCT06061718 | Sep 2023 → Mar 2024 | ocular hypertension, open-angle glaucoma | Glaukos Corporation | Unknown | No outcome recorded |
| Phase 3 | NCT03868124 | Sep 2018 → Jun 2022 | ocular hypertension, open-angle glaucoma | Glaukos Corporation | Completed | No outcome recorded |
| Phase 3 | NCT03519386 | Jul 2018 → Apr 2022 | ocular hypertension, open-angle glaucoma | Glaukos Corporation | Completed | Met primary |
| Phase 3 | NCT04061044 | Jul 2018 → Feb 2020 | open-angle glaucoma | Ocular Therapeutix, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02914509 | Nov 2016 → Mar 2019 | ocular hypertension, open-angle glaucoma | Ocular Therapeutix, Inc. | Completed | Missed primary |
| Phase 3 | NCT02390284 | Sep 2015 → Oct 2024 | glaucoma | University of Miami | Terminated | No outcome recorded |
| Phase 3 | NCT01652664 | Sep 2012 → Mar 2014 | glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT01453855 | Nov 2011 → Aug 2012 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT01452009 | Nov → Dec 2011 | ocular hypertension, open-angle glaucoma | Alcon Research | Withdrawn | No outcome recorded |
| Phase 3 | NCT01168414 | Aug 2010 → Jan 2011 | ocular hypertension, open-angle glaucoma | Ministry of Health, Malaysia | Completed | No outcome recorded |
| Phase 3 | NCT00912054 | Mar 2010 → May 2011 | ocular hypertension, open-angle glaucoma | Alcon Research | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00872651 | Jan 2010 → Nov 2011 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00892762 | Jun 2009 → May 2011 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00848536 | Mar 2009 → Jan 2010 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00767481 | Oct 2008 → Feb 2009 | glaucoma, ocular hypertension | Alcon Research | Terminated | No outcome recorded |
| Phase 3 | NCT00761319 | Oct 2008 → Sep 2009 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00690794 | Jul 2008 → May 2009 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00465803 | Mar 2007 → Jan 2009 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00333125 | Apr 2006 → Feb 2007 | glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00293761 | Jan → May 2006 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00051168 | Jan 2006 → Mar 2009 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00288951 | Oct 2004 → Jun 2005 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00293800 | Jul 2004 → Dec 2005 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00293787 | Jun 2004 → Aug 2005 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00311389 | Jan 2003 → Sep 2004 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00051142 | Feb 2001 → Jun 2004 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00051155 | Jan 2001 → Jul 2004 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00051181 | Jan 2000 → Jun 2003 | chronic closed-angle glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 432 trials · 2 met primary | ||||||
| Phase 4 | NCT07228221 | Jan 2026 → Aug 2031 expected | open-angle glaucoma | Jonathon Myers | Recruiting | No outcome recorded |
| Phase 4 | NCT06848946 | Jan 2025 → Aug 2026 overdue | cataract 50 with or without glaucoma, ocular hypertension, open-angle glaucoma | Glaukos Corporation | Recruiting | No outcome recorded |
| Phase 4 | NCT06066645 | Sep 2023 → May 2027 expected | open-angle glaucoma | Glaukos Corporation | Recruiting | No outcome recorded |
| Phase 4 | NCT04577027 | Jan 2021 → Jan 2022 | vitiligo | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT02796560 | Jul 2016 → Sep 2017 | ocular hypertension, open-angle glaucoma | University of Sherbrooke | Completed | No outcome recorded |
| Phase 4 | NCT03966560 | Jan 2014 → Jan 2015 | open-angle glaucoma | Afyon Kocatepe University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02003391 | Dec 2013 → May 2015 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | Met primary |
| Phase 4 | NCT01995136 | Sep 2013 → Jun 2014 | low tension glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01664039 | Sep 2012 → Jun 2014 | glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01510145 | Feb 2012 → May 2013 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01535768 | Feb 2012 → Jun 2018 | glaucoma | Credit Valley EyeCare | Unknown | No outcome recorded |
| Phase 4 | NCT01493427 | Dec 2011 → Feb 2013 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01978015 | Oct 2011 → Jul 2012 | anterior uveitis, cystoid macular edema | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 4 | NCT01464424 | Oct 2011 → Jun 2012 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | Met primary |
| Phase 4 | NCT01230736 | Oct 2010 → Feb 2011 | glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01159756 | Jul 2010 → Nov 2011 | ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00966940 | Sep 2009 → Mar 2010 | glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00798759 | Dec 2008 → May 2009 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00759239 | Sep 2008 → Jan 2011 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00708422 | Jul 2008 → Aug 2009 | glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00508469 | Oct 2007 → Jan 2010 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00519753 | Aug 2007 → Dec 2008 | glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00444665 | May → Aug 2007 | glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00527592 | May 2007 → Aug 2008 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00471068 | Mar 2007 → Aug 2008 | ocular hypertension, open-angle glaucoma | Alcon Research | Terminated | No outcome recorded |
| Phase 4 | NCT00762645 | Feb 2007 → May 2008 | angle-closure glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00763061 | May 2006 → Apr 2008 | glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00329095 | Dec 2005 → Apr 2006 | glaucoma, ocular hypertension | Robin, Alan L., M.D. | Completed | No outcome recorded |
| Phase 4 | NCT00308945 | Nov 2003 → Feb 2005 | open-angle glaucoma | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 4 | NCT00061503 | Apr 2003 → Mar 2004 | glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00347802 | — | glaucoma | Innovative Medical | Completed | No outcome recorded |
| Phase 4 | NCT00348023 | — | glaucoma | Innovative Medical | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT01711177 | Oct 2012 → Mar 2013 | open-angle glaucoma | University of Montreal | Completed | No outcome recorded |
| — | NCT01491867 | Dec 2011 → Oct 2012 | glaucoma, ocular hypertension | Semmelweis University | Completed | No outcome recorded |
| — | NCT01361841 | Jan 2009 → Jan 2012 | ocular hypertension, open-angle glaucoma | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | Unknown | No outcome recorded |
| — | NCT00441181 | Jan → Dec 2008 | neovascular glaucoma | Federal University of São Paulo | Withdrawn | No outcome recorded |
| — | NCT00435058 | Sep 2005 → Apr 2006 | glaucoma | University of Sao Paulo | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04962009 | Sep 2021 → Jul 2022 | ocular hypertension | Mati Therapeutics Inc. | Completed | No outcome recorded |
| Comparator or background therapy41 trials | ||||||
| Phase 1 | NCT03965052 Comparator | Apr → Jul 2019 | glaucoma | Laboratorios Sophia S.A de C.V. | Completed | No outcome recorded |
| Phase 2 | NCT02312544 Comparator | Nov 2014 → Sep 2015 | glaucoma, ocular hypertension | Ocular Therapeutix, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02140060 Comparator | Jun → Nov 2014 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 2 | NCT01789736 Comparator | Feb → Jun 2013 | ocular hypertension, open-angle glaucoma | Aerie Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01474135 Comparator | Dec 2011 → Apr 2012 | glaucoma, ocular hypertension | Aerie Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01312454 Comparator | Jun 2011 → Jan 2012 | ocular hypertension, open-angle glaucoma | Alcon Research | Terminated | No outcome recorded |
| Phase 2 | NCT01114893 Comparator | Apr → May 2010 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 2 | NCT00670033 Comparator | Apr → Sep 2008 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT01004900 Comparator | Jun 2009 → Mar 2011 | glaucoma | Singapore Eye Research Institute | Unknown | No outcome recorded |
| Phase 3 | NCT00767494 Comparator | Oct 2008 → Feb 2009 | ocular hypertension, open-angle glaucoma | Alcon Research | Terminated | No outcome recorded |
| Phase 3 | NCT00672997 Background | May → Dec 2008 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00980473 Comparator | Sep 2007 → Sep 2011 | glaucoma | Singapore National Eye Centre | Unknown | No outcome recorded |
| Phase 4 | NCT03150160 Background | Sep → Dec 2017 | glaucoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02730871 Background | Jun 2016 → Jul 2018 | ocular hypertension, open-angle glaucoma | Alcon Research | Terminated | Met primary Stop: Enrollment |
| Phase 4 | NCT02419508 Background | Aug 2015 → Feb 2018 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | Met primary |
| Phase 4 | NCT02097719 Comparator | May → Dec 2014 | glaucoma, ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT02105311 Comparator | Mar 2014 → Feb 2016 | — | Prince of Songkla University | Completed | No outcome recorded |
| Phase 4 | NCT01937299 Background | Oct 2013 → Apr 2014 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01881126 Comparator | Jun 2013 → Oct 2014 | glaucoma, ocular hypertension | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT02873806 Background | Mar 2013 → Nov 2019 | open-angle glaucoma | Glaukos Corporation | Completed | No outcome recorded |
| Phase 4 | NCT01547598 Comparator | Dec 2011 → Jul 2013 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT01443988 Comparator | Sep 2011 → Jan 2017 | open-angle glaucoma | Glaukos Corporation | Completed | No outcome recorded |
| Phase 4 | NCT01444040 Comparator | Sep 2011 → Mar 2019 | open-angle glaucoma | Glaukos Corporation | Completed | No outcome recorded |
| Phase 4 | NCT01263444 Background | Mar 2011 → Apr 2013 | glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT01315574 Comparator | Feb 2011 → Dec 2013 | glaucoma | Massachusetts Eye and Ear Infirmary | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01253902 Comparator | Dec 2010 → Oct 2011 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT00981786 Comparator | Aug 2009 → Sep 2010 | glaucoma | Aristotle University Of Thessaloniki | Completed | No outcome recorded |
| Phase 4 | NCT00887029 Comparator | Jan → Nov 2009 | ocular hypertension, open-angle glaucoma | Ophthalmic Consultants Centres, Canada | Completed | No outcome recorded |
| Phase 4 | NCT02136589 Background | Sep → Dec 2008 | ocular hyperemia | Tokyo University | Completed | No outcome recorded |
| Phase 4 | NCT00705757 Comparator | Mar 2008 → Apr 2011 | glaucoma, hyperpigmentation of the skin | Summa Health System | Completed | No outcome recorded |
| Phase 4 | NCT00539526 Comparator | Sep 2007 → Jul 2008 | ocular hypertension, open-angle glaucoma | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT00444184 Comparator | Mar 2007 → Jan 2008 | glaucoma | Aristotle University Of Thessaloniki | Completed | No outcome recorded |
| Phase 4 | NCT00471380 Comparator | Mar 2007 → Oct 2008 | glaucoma, ocular hypertension | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00440011 Comparator | Aug 2006 → Oct 2007 | glaucoma, ocular hypertension | Allergan | Completed | Met primary |
| Phase 4 | NCT00758342 Comparator | May 2006 → Mar 2008 | — | Alcon Research | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00372827 Background | Feb 2004 → Jan 2006 | ocular hypertension, open-angle glaucoma, pigment dispersion syndrome | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00847483 Comparator | Jan → Aug 2002 | glaucoma, ocular hypertension | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01655758 Comparator | Jan 2002 → Dec 2003 | ocular hypertension | University of Parma | Completed | No outcome recorded |
| — | NCT05241938 Comparator | Sep 2021 → Dec 2022 | ocular hypertension, open-angle glaucoma | Federal University of Rio Grande do Sul | Unknown | No outcome recorded |
| — | NCT04868175 Comparator | Oct 2019 → Mar 2021 | glaucoma | The University of Hong Kong | Completed | No outcome recorded |
| — | NCT00121147 Background | Sep 2003 → Oct 2005 | exfoliation syndrome, ocular hypertension, open-angle glaucoma | Hermann Eye Center | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 28
| Date | Issuer | Release |
|---|---|---|
| 2026-10-09 | Glaukos Corporation | Results Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery glaukos.com ↗
The study achieved its primary efficacy endpoint, with iDose TR demonstrating statistically significant superiority in the reduction of mean diurnal intraocular pressure (IOP) when administered in conjunction with cataract surgery compared to cataract surgery alone. |
| 2026-01-28 | Glaukos Corporation | Regulatory Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR glaukos.com ↗ |
| 2025-12-01 | Alembic Pharmaceuticals Ltd. | Regulatory 18th December, 2025 Vadodara, India alembicpharmaceuticals.com ↗
Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution). |
| 2025-01-14 | Glaukos Corporation | Results Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform glaukos.com ↗
In addition,iDose TR continued to demonstrate excellent tolerability and a favorable safety profile through 36 months across both Phase 3 trials. |
| 2024-05-06 | Lupin Limited | Regulatory Lupin Receives Approval from U.S. FDA for Travoprost Ophthalmic Solution USP lupin.com ↗
Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Travoprost Ophthalmic Solution USP, 0.004%(Ionic Buffered Solution), to market a generic equivalent to the reference listed drug (RLD)Travatan Z® Ophthalmic Solution, 0.004%, of Sandoz Inc. |
| 2024-04-06 | Ocular Therapeutix, Inc. | Results Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting ocutx.com ↗
Ocular is very pleased to report positive six-month topline results for PAXTRAVA in the Phase 2 glaucoma study. |
| 2023-12-14 | Glaukos Corporation | Regulatory Glaukos Announces FDA Approval of iDose®TR (travoprost intracameral implant) glaukos.com ↗ |
| 2023-05-05 | Glaukos Corporation | Regulatory Glaukos Announces FDA Acceptance of NDA Submission for iDose TR glaukos.com ↗
“The acceptance of the iDose TR NDA represents another important step in bringing this potential game-changing therapy one step closer to patients who may need a new treatment alternative,” said Thomas Burns, Glaukos chairman and chief executive officer. |
| 2023-02-27 | Glaukos Corporation | Regulatory Glaukos Submits New Drug Application to U.S. FDA for iDose TR glaukos.com ↗
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iDose® TR. |
| 2023-01-10 | Glaukos Corporation | Results Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerability glaukos.com ↗
Results from the exchange trial demonstrated a second administration of iDose TR and removal of the original iDose TR implant was safe and well-tolerated, with the second iDose TR demonstrating a favorable safety profile over a 12-month evaluation period. |
| 2022-09-07 | Glaukos Corporation | Results Glaukos Announces Positive Topline Outcomes for Both Phase 3 Pivotal Trials of iDose TR, Achieving Primary Efficacy Endpoints and Demonstrating Favorable Tolerability and Safety Profiles glaukos.com ↗ |
| 2022-01-11 | Glaukos Corporation | Results Glaukos’ iDose®TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 36 Months in Phase 2b Study glaukos.com ↗
today announced that its iDose® TR sustained-release travoprost implant continued to provide sustained substantial reductions in intraocular pressure (IOP) in a 36-month analysis of the 36-month Phase 2b clinical trial conducted under a U.S. Investigational New Drug (IND) protocol. |
| 2021-10-28 | Ocular Therapeutix, Inc. | Results Ocular Therapeutix™ to Present Data at the American Academy of Ophthalmology (AAO) 2021 Virtual Annual Meeting ocutx.com ↗
Phase 1 clinical trial assessing the safety and biological activity of a single intracameral travoprost implant (OTX-TIC) in glaucoma or ocular hypertension subjects showed a reduction in IOP as least as good as topical travoprost |
| 2021-05-05 | Ocular Therapeutix, Inc. | Results Ocular Therapeutix™ Reports First Quarter 2021 Financial Results and Business Update ocutx.com ↗
Updated interim analyses of Phase 1 data for both OTX-TKI for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases and OTX-TIC for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension were presented. |
| 2021-01-20 | Ocular Therapeutix, Inc. | Results Ocular Therapeutix™ Presents Interim Topline Data from the Phase 1 Clinical Trial of OTX-TIC in Patients with Primary Open Angle Glaucoma or Ocular Hypertension at the 10th Annual Glaucoma 360 New Horizons Forum ocutx.com ↗
In this Phase 1 clinical trial, all cohorts experienced a mean reduction in IOP from baseline of 7-11 mm Hg with onset of action as early as two days after insertion. |
| 2021-01-13 | Glaukos Corporation | Results Glaukos’ iDose® TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 24 Months in Phase 2b Study glaukos.com ↗ |
| 2020-02-07 | Ocular Therapeutix, Inc. | Results Ocular Therapeutix™ Presents Data Demonstrating a Clinically-Meaningful Reduction in Intraocular Pressure in Patients with Primary Open Angle Glaucoma or Ocular Hypertension Treated with OTX-TIC at Glaucoma 360 Conference ocutx.com ↗
Data from this Phase 1 clinical trial demonstrated a clinically-meaningful reduction in intraocular pressure (IOP) for up to 18 months in these patients treated with a single insertion of OTX-TIC. |
| 2019-12-01 | Alembic Pharmaceuticals Ltd. | Regulatory 24th December, 2019, Vadodara, India alembicpharmaceuticals.com ↗
Alembic Pharmaceuticals Limited (Alembic) today announced that the Company has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Travoprost Ophthalmic Solution USP, 0.004%. |
| 2019-05-20 | Ocular Therapeutix, Inc. | Results Ocular Therapeutix™ Announces Topline Results of Phase 3 Clinical Trial of OTX-TP for the Treatment of Glaucoma ocutx.com ↗
Topline results show that the trial did not achieve its primary endpoint of statistically significant superiority in mean reduction of IOP compared with placebo at all nine time points. |
| 2019-04-15 | Glaukos Corporation | Results Prospective, Randomized Trial Highlights 5-Year Performance of 2 Standalone Glaukos iStents® vs. Topical Prostaglandin in Newly Diagnosed Glaucoma Patients glaukos.com ↗
At five years, results showed: Mean diurnal IOP was 16.5 mmHg (35.3% reduction; p < 0.0001) for the stent group vs. 16.3 mmHg (35.1% reduction) for the travoprost group, excluding eyes in both cohorts that underwent cataract surgery during follow-up. |
| 2018-01-10 | Glaukos Corporation | Results Glaukos Corporation’s iDose™ Travoprost Achieves Sustained IOP Reduction and Favorable Safety Profile in 12-Month Interim Cohort glaukos.com ↗
today announced that its Travoprost Intraocular Implant with the iDose™ delivery system continued to provide sustained reduction in intraocular pressure (IOP) in a 12-month interim cohort of patients in its U.S. Investigational New Drug (IND) Phase II clinical trial. |
| 2017-06-21 | Glaukos Corporation | Results Combining Implantation of Glaukos iStent inject® Trabecular Micro-Bypass with Topical Travoprost Provides Sustained IOP Reduction and Favorable Safety Profile, According to New Study glaukos.com ↗
At 12 months, 100% of eyes achieved IOP ≤ 18 mm Hg, and 87% of eyes achieved IOP ≤ 15 mm Hg, with the reduction of one medication. |
| 2017-04-13 | Glaukos Corporation | Results International Study Shows Two Glaukos iStent® Trabecular Micro-Bypass Stents and One Topical Medication Deliver Sustained IOP Reduction glaukos.com ↗
Through three years, 86% of eyes achieved IOP ≤ 18 mm Hg. |
| 2016-09-22 | Glaukos Corporation | Results International Study Shows Favorable 3-Year Results of 2 Glaukos iStent® Trabecular Micro-Bypass Stents as Initial Treatment for Naïve Glaucoma glaukos.com ↗
11% of eyes in the stent group required additional topical medication therapy, compared to 23% in the travoprost group. |
| 2016-01-07 | Glaukos Corporation | Regulatory Glaukos Will Begin Phase II Clinical Trial for iDose™ Travoprost Intraocular Implant in Glaucoma Patients glaukos.com ↗ |
| 2015-11-19 | Glaukos Corporation | Regulatory Glaukos Submits IND Application to FDA to Study iDoseTM Travoprost Intraocular Implant in Glaucoma Patients glaukos.com ↗
This IND submission represents a seminal milestone, which the Glaukos team achieved well ahead of our original 2016 timeline, |
| 2015-11-10 | Ocular Therapeutix, Inc. | Results Ocular Therapeutix™ Reports Third Quarter 2015 Financial Results ocutx.com ↗
Topline results from a Phase 2b clinical trial were announced for the Company’s OTX-TP product candidate for the treatment of glaucoma and ocular hypertension, showing clinically meaningful intraocular pressure (IOP) reduction out to day 90 and improvement in depot retention. |
| 2015-10-22 | Ocular Therapeutix, Inc. | Results Ocular TherapeutixTM Reports on Topline Results of Phase 2b Glaucoma Clinical Trial ocutx.com ↗
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced topline results through 90 days of therapy from its Phase 2b clinical trial of OTX-TP (sustained release travoprost) for the treatment of glaucoma and ocular hypertension. |
All press releases naming this drug 38 releases
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 125 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | travoprost | “To evaluate the safety and IOP lowering efficacy of OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid compared to Timolol Maleate...” NCT02312544 ↗119“a topical prostaglandin analogue eye drop. (latanoprost 0.005% 1 gtts in study eye qhs OR travoprost 0.004% 1 gtts in study eye qhs OR bimatoprost 0.01% 1 gtts in study eye qhs...” NCT01535768 ↗ “To assess the safety, tolerability and efficacy of a single sustained release dose of OTX-TIC, a sustained release travoprost drug product, in subjects with primary open-angle...” NCT04360174 ↗ “Travacom(R) is a combination topical ocular agent, containing travoprost and timolol, which lower intraocular pressure (IOP) by complementary mechanisms of action.” NCT01159756 ↗ “Patients were surveyed using the Ocular Surface Disease Index (OSDI) to evaluate OSD symptoms prior to changing to travoprost BAK-free dosed once every evening.” PMID 19668762 ↗ Sep 2008 “Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.” NCT00690794 ↗ “Fixed combination of Travoprost and Timolol (TTFC; Duotrav (40 micrograms + 5 mg/ml eyedrops solution)” NCT01168414 ↗ “Prostaglandin analogue eye drops (latanoprost, bimatoprost or travoprost) will be prescribed” NCT05241938 ↗ “travoprost APS 40 micrograms/ml / timolol 5 mg/ml, Eye Drops, Solution, once daily” NCT00912054 ↗ “OTX-TPa is a hydrogel punctum plug eluting travoprost in a sustained release” NCT01845038 ↗ “Generic name: Travoprost * Distinctive denomination: Bristrio® (PRO-179)” NCT03965052 ↗ |
| Known as | ENV515-1 | “ENV515-1 Travoprost XR” NCT02371746 ↗ |
| Known as | ENV515-3 | “ENV515-3 Travoprost XR” NCT02371746 ↗ |
| Known as | ENV515-3-2 | “ENV515-3-2 Travoprost XR” NCT02371746 ↗ |
| Known as | Gen 2 Travoprost Intracameral Implant | “Drug: Gen 2 Travoprost Intracameral Implant” NCT07075718 ↗ |
| Known as | iDose TR | “iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery” NCT06848946 ↗ |
| Known as | OTX-TIC | “To assess the safety, tolerability and efficacy of a single sustained release dose of OTX-TIC, a sustained release travoprost drug product, in subjects with primary open-angle...” NCT04360174 ↗1“OTX-TIC (travoprost) intracameral implant” NCT05335122 ↗ |
| Known as | OTX-TP | “To evaluate the safety and IOP lowering efficacy of OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid compared to Timolol Maleate...” NCT02312544 ↗ |
| Known as | TRAV | “BAK-free travoprost 0.004% (TRAV) and BAK 0.02%-preserved bimatoprost 0.01% (BIM) during late-day time points in patients with open-angle glaucoma or ocular hypertension.” PMID 25432143 ↗ Nov 2014 |
| Known as | Travatan | “Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)” NCT00758342 ↗9“Travatan: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution)” NCT00471068 ↗ “Travatan/travoprost 0.004% ophthalmic solution one drop qhs for one year” NCT00705757 ↗ “Travoprost Ophthalmic Solution, 0.004% (Travatan), a prostaglandin” NCT00121147 ↗ “Generic name: Travoprost * Distinctive denomination: Travatan®” NCT03965052 ↗ “Travoprost 0.004% Ophthalmic Solution (Travatan)” NCT00763061 ↗ “Drug: Travoprost 0.004% (Travatan)” NCT00762645 ↗ |
| Known as | TRAVATAN PQ (Travoprost ophthalmic solution with PQ, 0.004%) | “TRAVATAN® PQ (Travoprost ophthalmic solution with PQ, 0.004%)” NCT02419508 ↗ |
| Known as | Travatan TM | “Three of these are commonly used in North America: latanoprost (Latanoprost T, Pfizer), Travoprost (Travatan TM, Alcon) and bimatoprost (Lumigan TM, Allergan).” NCT01361841 ↗ |
| Known as | Travatan Z | “PURPOSE: To compare the duration of action of travoprost ophthalmic solution
0.004% (Travatan Z) formulated without benzalkonium chloride (BAK) to travoprost
ophthalmic...” PMID 18414108 ↗ Apr 20081“Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy” NCT00444665 ↗ |
| Known as | Travatan(R) Z | “Travatan(R) Z(travoprost ophthalmic solution)” NCT01474135 ↗ |
| Action | Activate | “Travoprost (0.0015% and 0.004%), a highly selective, potent prostaglandin F (FP) receptor agonist” PMID 11589866 ↗ Oct 2001 |
| Modality | Other / unclassified | “Travoprost (0.0015% and 0.004%), a highly selective, potent prostaglandin F (FP) receptor agonist” PMID 11589866 ↗ Oct 2001 |
| Route | Topical | “1 drop each eye once daily” NCT00051168 ↗ |